BioXcel Therapeutics, Inc.
(NASDAQ : BTAI)

( )
BTAI PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -0.61%77.731.0%$1898.73m
AMGNAmgen, Inc. 3.00%211.581.3%$929.21m
REGNRegeneron Pharmaceuticals, Inc. 2.22%504.272.6%$852.10m
BIIBBiogen, Inc. 3.62%311.391.5%$796.11m
VRTXVertex Pharmaceuticals, Inc. 7.13%255.301.9%$652.54m
MRNAModerna, Inc. -0.57%34.640.0%$571.40m
ILMNIllumina, Inc. 5.51%278.013.5%$493.14m
ALXNAlexion Pharmaceuticals, Inc. 6.84%95.912.0%$303.02m
AAgilent Technologies, Inc. 5.47%74.281.6%$229.86m
INCYIncyte Corp. 8.30%85.112.5%$212.70m
EXASEXACT Sciences Corp. 11.70%62.2721.0%$179.74m
SGENSeattle Genetics, Inc. 6.83%124.476.1%$170.36m
BMRNBioMarin Pharmaceutical, Inc. -1.71%82.774.3%$160.44m
NVAXNovavax, Inc. 3.14%16.10114.7%$125.40m
IMMUImmunomedics, Inc. 99.79%18.7811.9%$114.76m

Company Profile

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.